Physician profile
Lourdes Castanon
NPI 1790913267
$41,231.48
in general payments reported to CMS, 2019-2025
15 companies · $21K in 2025
The $21K reported for 2025 was more than what 98% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $52.56 · 2021: $176 · 2022: $2,376 · 2023: $16K · 2024: $1,912 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $3,046 · Food and Beverage: $2,174 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,645.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,633.75 |
| Travel and Lodging | $3,045.62 |
| Food and Beverage | $2,174.48 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $25,053.57 | 2019-2025 | Oasis, Collagenase Santyl, Versajet |
| Avita Medical Americas, LLC | $11,740.93 | 2020-2025 | Recell, Permeaderm, Cohealyx |
| Integra Lifesciences Corporation | $3,854.95 | 2021-2025 | Codman Certas, Surgimend, Integra |
| Aroa Biosurgery Incorporated | $142.92 | 2022 | |
| Polymedics Innovations INC. | $101.83 | 2023 | |
| Kerecis Limited | $61.46 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Polynovo North America LLC | $52.48 | 2020-2021 | |
| Polarityte, INC. | $48.64 | 2019 | |
| Cardinal Health 200 LLC | $32.85 | 2019 | |
| Teleflex LLC | $31.26 | 2022 | |
| Molnlycke Health Care US, LLC | $25.60 | 2025 | Mepilex Border Ag, Mepilex Transfer Ag, Melgisorb Plus |
| Kls-Martin L.P. | $23.15 | 2020 | |
| Glaxosmithkline, LLC. | $22.91 | 2025 | Nucala |
| La Jolla Pharmaceutical Company | $21.23 | 2023 | Xerava |
| Vericel Corporation | $17.70 | 2023 | Nexobrid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Castanon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.